Pliant Therapeutics Dirección
Dirección controles de criterios 2/4
Actualmente no disponemos de información suficiente sobre el CEO.
Información clave
Bernard Coulie
Chief Executive Officer (CEO)
US$11.2m
Compensación total
| Porcentaje del salario del CEO | 5.5% |
| Permanencia del CEO | 8.6yrs |
| Participación del CEO | 1.1% |
| Permanencia media de la dirección | 8.5yrs |
| Promedio de permanencia en la Junta Directiva | 6.9yrs |
Actualizaciones recientes de la dirección
Recent updates
Is Pliant Therapeutics (NASDAQ:PLRX) Using Too Much Debt?
Sep 13
Pliant Therapeutics: Good Data, But Will Need Watching
Sep 11Should Shareholders Reconsider Pliant Therapeutics, Inc.'s (NASDAQ:PLRX) CEO Compensation Package?
Jun 07Is Pliant Therapeutics (NASDAQ:PLRX) Weighed On By Its Debt Load?
Feb 27Is Pliant Therapeutics (NASDAQ:PLRX) Using Debt Sensibly?
Jul 21Health Check: How Prudently Does Pliant Therapeutics (NASDAQ:PLRX) Use Debt?
Mar 13Is Pliant Therapeutics (NASDAQ:PLRX) Weighed On By Its Debt Load?
Sep 10Pliant Therapeutics: Wait For A Better Price To Get In
Aug 20Pliant Therapeutics GAAP EPS of -$0.82 misses by $0.01, revenue of $4.99M
Aug 08Is Pliant Therapeutics (NASDAQ:PLRX) In A Good Position To Deliver On Growth Plans?
Jul 28Pliant's PLN-74809 gets FDA fast track status for liver disease
Jul 21Pliant climbs 48% as mid-stage trial for lung disease therapy meets key goals
Jul 11Pliant: Major Catalyst Expected Beginning Of 2023
Jun 03We're Keeping An Eye On Pliant Therapeutics' (NASDAQ:PLRX) Cash Burn Rate
Apr 22Here's Why We're Not Too Worried About Pliant Therapeutics' (NASDAQ:PLRX) Cash Burn Situation
Dec 29We Think Pliant Therapeutics (NASDAQ:PLRX) Can Afford To Drive Business Growth
Sep 07Analysts Have Just Cut Their Pliant Therapeutics, Inc. (NASDAQ:PLRX) Revenue Estimates By 12%
May 17Pliant Therapeutics, Inc. (NASDAQ:PLRX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
May 13Pliant Therapeutics (NASDAQ:PLRX) Is In A Good Position To Deliver On Growth Plans
Mar 22We're Not So Sure You Should Rely on Pliant Therapeutics's (NASDAQ:PLRX) Statutory Earnings
Jan 21
Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$185m |
| Mar 31 2024 | n/a | n/a | -US$171m |
| Dec 31 2023 | US$11m | US$610k | -US$161m |
| Sep 30 2023 | n/a | n/a | -US$155m |
| Jun 30 2023 | n/a | n/a | -US$144m |
| Mar 31 2023 | n/a | n/a | -US$133m |
| Dec 31 2022 | US$11m | US$587k | -US$123m |
| Sep 30 2022 | n/a | n/a | -US$113m |
| Jun 30 2022 | n/a | n/a | -US$109m |
| Mar 31 2022 | n/a | n/a | -US$103m |
| Dec 31 2021 | US$5m | US$556k | -US$97m |
| Sep 30 2021 | n/a | n/a | -US$92m |
| Jun 30 2021 | n/a | n/a | -US$81m |
| Mar 31 2021 | n/a | n/a | -US$75m |
| Dec 31 2020 | US$2m | US$499k | -US$42m |
| Sep 30 2020 | n/a | n/a | US$18m |
| Jun 30 2020 | n/a | n/a | US$19m |
| Mar 31 2020 | n/a | n/a | US$20m |
| Dec 31 2019 | US$2m | US$428k | -US$7m |
Compensación vs. Mercado: La compensación total de Bernard($USD11.17M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD3.30M).
Compensación vs. Ingresos: La compensación de Bernard ha aumentado mientras la empresa no es rentable.
CEO
Bernard Coulie (57 yo)
8.6yrs
Permanencia
US$11,165,999
Compensación
Dr. Bernard Coulie, Ph D, M.D. M.B.A. is Director of Septerna, Inc. from February 2024. He serves as Independent Director at SQZ Biotechnologies Company since July 2021 and serves as its Independent Chairm...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | no data | US$11.17m | 1.1% $ 7.5m | |
| Chief Financial Officer | 5.8yrs | US$4.44m | 0.31% $ 2.2m | |
| General Counsel & Corporate Secretary | 3.9yrs | US$3.32m | 0.060% $ 413.3k | |
| Chief Business Officer | 8.5yrs | US$4.36m | 0.32% $ 2.2m | |
| Chief Medical Officer | 6.3yrs | US$4.69m | 0.22% $ 1.5m | |
| Scientific Founder & Member of Scientific Advisory Board | 9.7yrs | sin datos | sin datos | |
| Scientific Founder & Member of Scientific Advisory Board | 9.7yrs | sin datos | sin datos | |
| Scientific Founder & Member of Scientific Advisory Board | 9.7yrs | sin datos | sin datos | |
| Scientific Founder & Member of Scientific Advisory Board | 9.7yrs | sin datos | sin datos | |
| Interim Chief Technology Officer | no data | sin datos | sin datos | |
| Vice President of Investor Relations & Corporate Communications | no data | sin datos | sin datos | |
| Chief Human Resources Officer | 1.7yrs | sin datos | 0.0013% $ 9.0k |
8.5yrs
Permanencia media
51yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de PLRX es experimentado (8.4 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | 8.6yrs | US$11.17m | 1.1% $ 7.5m | |
| Scientific Founder & Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Scientific Founder & Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Scientific Founder & Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Scientific Founder & Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Independent Director | 4.8yrs | US$278.71k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Independent Director | 8.2yrs | US$277.21k | 0.058% $ 396.8k | |
| Independent Director | 7.1yrs | US$271.96k | 0.048% $ 331.1k | |
| Independent Chairman | 6.8yrs | US$296.71k | 0.16% $ 1.1m | |
| Independent Director | 5.5yrs | US$277.96k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos |
6.9yrs
Permanencia media
61yo
Promedio de edad
Junta con experiencia: La junta directiva de PLRX se considera experimentada (6.8 años de antigüedad promedio).